Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Hair Preservation Improved by 50% with Investigational Scalp-Cooling Device
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—The use of an investigational electronic scalp-cooling device in patients with breast cancer who had received alopecia-inducing chemotherapy resulted in reduced or no hair loss in 50% of the patients, according to results of a randomized clinical trial reported at the 2016 San Antonio Breast Cancer Symposium. By contrast, no patient in the control group had hair preservation.
Read Article
Good News for a Different Type of CDK4/CDK6 Inhibitor in Early Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—Neoadjuvant therapy with the investigative CDK4/CDK6 inhibitor abemaciclib, alone or in combination with anastrozole (Arimidex), showed promising activity in postmenopausal hormone receptor (HR)-positive, HER2-negative breast cancer enrolled in the phase 2 NeoMONARCH study. Correlative tissue studies demonstrated that abemaciclib inhibited cell-cycle proliferation and activated the immune system, supporting its anticancer activity. Abemaciclib received a breakthrough therapy designation in 2015 as monotherapy for the treatment of patients with refractory HR-positive advanced breast cancer in heavily pretreated patients.
Read Article
Adding Everolimus to Antiestrogen Therapy Doubles Progression-Free Survival in Advanced Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
,
Personalized Medicine
April 2017, Vol 8, No 2
San Antonio, TX—The addition of the mTOR inhibitor everolimus (Afinitor) to the antiestrogen chemotherapy fulvestrant (Faslodex) led to a 2-fold increase in progression-free survival (PFS) in patients with advanced hormone receptor (HR)-positive breast cancer compared with fulvestrant alone, according to results of a randomized clinical trial presented at the 2016 San Antonio Breast Cancer Symposium.
Read Article
Increasing Patient Enrollment in Clinical Trials Key to Progress in Cancer Care
By
Jessica Miller
Clinical Trials
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Patient involvement in clinical trials will impact the Cancer Moonshot’s goal of achieving 10 years of progress in 5 years’ time, said Kim Thiboldeaux, Chief Executive Officer, Cancer Support Community, Washington, DC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice
By
Wayne Kuznar
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Cancer is now recognized as a disease of the genome. The use of genomic assays and measurement of protein expression are permitting the use of personalized cancer therapy in the clinical setting on a scale not seen previously. In many cases, the use of these assays will also enhance the cost-effectiveness of cancer therapy, although the overall cost of cancer care may not decline as a result, said Gerald Messerschmidt, MD, FACP, Chief Medical Officer, Precision for Medicine, at the Sixth Annual Conference of the Association for ValueBased Cancer Care.
Read Article
Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—The Cancer Moonshot 2020 program is exploring a new paradigm in cancer care by bringing clinical trials focused on immunotherapy to community and academic practices. This privately funded initiative seeks to conduct phase 2 clinical trials within the next 36 months in 20,000 patients with >20 tumor types at all stages of cancer, said Gary Palmer, MD, JD, MPH, Chief Medical Officer, President, GPS Operations, NantHealth, Culver City, CA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Precision Medicine the Future of Cancer Care, but Cost Remains a Major Barrier
By
David Knight
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Precision medicine is the optimal approach to the future of cancer care, but unless a new pricing model for innovative treatments is implemented, the cost of care will be the greatest barrier to effective treatment, said Maurie Markman, MD, President, Cancer Treatment Centers of America, and Clinical Professor of Medicine, Drexel University, Philadelphia, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Plethora of Targeted Agents in the Oncology Pipeline
By
David Knight
Emerging Therapies
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—The oncology pipeline is bustling and shows no sign of slowing down anytime soon, said Anita Dopkosky, RPh, MS, Director, National Accounts, Walgreens, Pittsburgh, PA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care. She provided an overview of key drugs in the oncology pipeline.
Read Article
Trajectory of Illness and Distress in Patients Undergoing Stem-Cell Transplantation
By
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
San Francisco, CA—As a result of recent advances in therapy, indications for stem-cell transplant are expanding, along with the number of patients eligible for the procedure. However, the intense and cure-oriented nature of transplants can lead to various forms of distress in patients who undergo this treatment, said Christina K. Ullrich, MD, MPH, Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2016 Palliative Care in Oncology Symposium.
Read Article
Disparities in Rehospitalization Rates Among Patients with Advanced Cancer
By
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
San Francisco, CA—In addition to being costly for public and private payers, hospital readmissions can lead to increased risk for complications, hospital-acquired infections, and psychological distress in patients with advanced cancer. Although preventing readmissions would improve patient outcomes and decrease healthcare costs, the underlying causes of rehospitalization are not completely understood, suggested Robin L. Whitney, RN, PhD, Betty Irene Moore School of Nursing, University of California, Davis, and colleagues in a poster presentation at the 2016 Palliative Care in Oncology Symposium.
Read Article
Page 12 of 35
7
8
9
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma